Dashboard
Manage Tickers

ONCT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

northland-capital-markets-downgrades-oncternal-therapeutics-to-market-perform-announces-2-price-target
Northland Capital Markets Downgrades Oncte...
09/12/2024 19:49:17

Northland Capital Markets analyst Carl Byrnes downgrades Oncternal Therapeutics (NASDAQ:ONCT) from Outperform to Market Perf...

dow-surges-over-100-points-modivcare-shares-plummet
Dow Surges Over 100 Points; ModivCare Shar...
09/12/2024 18:01:18

crude-oil-surges-3-kroger-posts-upbeat-earnings
Crude Oil Surges 3%; Kroger Posts Upbeat E...
09/12/2024 16:10:01

brookline-capital-downgrades-oncternal-therapeutics-to-hold
Brookline Capital Downgrades Oncternal The...
09/12/2024 15:16:58

Brookline Capital analyst Kemp Dolliver downgrades Oncternal Therapeutics (NASDAQ:ONCT) from Buy to Hold.

us-stocks-mixed-producer-prices-increase-in-august
US Stocks Mixed; Producer Prices Increase ...
09/12/2024 14:23:57

trading-halt-halt-status-updated-at-94000-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 9:40:...
09/12/2024 13:40:05

oncternal-therapeutics-to-discontinue-clinical-trials-for-onct-534-and-onct-808-due-to-lack-of-clinically-meaningful-results-and-high-capital-requirements-company-to-explore-strategic-alternatives-including-asset-sales-licensing-or-mergers-while-reducing-workforce-to-preserve-cash-resources
Oncternal Therapeutics To Discontinue Clin...
09/12/2024 13:01:48

trading-halt-halted-at-85500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 8:55:00 a.m. ET - ...
09/12/2024 12:55:04

hc-wainwright--co-maintains-buy-on-oncternal-therapeutics-lowers-price-target-to-18
HC Wainwright & Co. Maintains Buy on Oncte...
08/12/2024 09:52:15

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and lowers the ...

oncternal-therapeutics-q2-2024-gaap-eps-289-beats-310-estimate-sales-801000k-beat-237500k-estimate
Oncternal Therapeutics Q2 2024 GAAP EPS $(...
08/08/2024 20:24:23

Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(2.89) per share which beat the analyst consensus estimate o...

hc-wainwright--co-reiterates-buy-on-oncternal-therapeutics-maintains-19-price-target
HC Wainwright & Co. Reiterates Buy on Onct...
07/16/2024 11:53:03

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains ...

oncternal-therapeutics-completes-enrollment-and-begins-dosing-for-sixth-dose-cohort-in-phase-12-study-of-onct-534-for-metastatic-castration-resistant-prostate-cancer
Oncternal Therapeutics Completes Enrollmen...
07/15/2024 12:08:25

Patients Receiving 1200 mg Daily Dose; Safety Review Committee Approved Higher Dose After Reviewing 600 mg Data; Initial Safety...

hc-wainwright--co-reiterates-buy-on-oncternal-therapeutics-maintains-19-price-target
HC Wainwright & Co. Reiterates Buy on Onct...
05/31/2024 10:12:14

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains ...

oncternal-completes-enrollment-and-dosing-initiated-for-5th-dose-cohort-of-phase-12-study-of-onct-534-for-the-treatment-of-rr-metastatic-castration-resistant-prostate-cancer
Oncternal Completes Enrollment And Dosing ...
05/30/2024 20:45:23

Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel onco...

hc-wainwright--co-maintains-buy-on-oncternal-therapeutics-lowers-price-target-to-19
HC Wainwright & Co. Maintains Buy on Oncte...
05/13/2024 12:01:31

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and lowers the ...

oncternal-therapeutics-q1-2024-gaap-eps-283-beats-288-estimate-sales-569000k-beat-176667k-estimate
Oncternal Therapeutics Q1 2024 GAAP EPS $(...
05/09/2024 20:22:53

Oncternal Therapeutics (NASDAQ:ONCT) reported quarterly losses of $(2.83) per share which beat the analyst consensus estimate o...

oncternal-announces-first-patient-dosed-in-fourth-cohort-of-phase-12-study-of-onct-534-for-the-treatment-of-rr-metastatic-castration-resistant-prostate-cancer
Oncternal Announces First Patient Dosed In...
04/18/2024 13:04:17

Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel onco...

hc-wainwright--co-maintains-buy-on-oncternal-therapeutics-lowers-price-target-to-28
HC Wainwright & Co. Maintains Buy on Oncte...
04/15/2024 10:10:16

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and lowers the ...

insiders-buying-westlake-chemical-partners-and-2-other-stocks
Insiders Buying Westlake Chemical Partners...
04/02/2024 13:06:23

Although U.S. stocks closed mostly lower on Monday, there were a few notable insider trades.

recap-oncternal-therapeutics-q4-earnings
Recap: Oncternal Therapeutics Q4 Earnings
03/07/2024 21:25:12

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION